ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73% in people with established cardiovascular disease and obesity compared with placebo, regardless of baseline A1c levels, according to two new analyses of the SELECT trial…
